At a glance
- Originator Pfizer
- Class Antithrombotics
- Mechanism of Action Thromboxane A2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 23 Jun 2000 Pfizer has merged with Warner-Lambert
- 03 May 2000 Profile reviewed but no significant changes have been made
- 25 Aug 1999 New profile